Google co-founder Sergey Brin’s foundation backed a major Parkinson’s study; in 2023, researchers validated a test that could detect disease-linked biology before movement symptoms appeared
The Sergey Brin Family Foundation, a private philanthropic organisation established in 2014 by Google co-founder Sergey Brin, supports a variety of important issues. These include research to understand, treat and improve the lives of people with central nervous system conditions and accelerating next-generation energy innovation. The foundation has also backed researchers who are running the Parkinson’s Progression Markers Initiative (PPMI) and achieved a major scientific milestone in 2023 by validating a biological test capable of spotting Parkinson’s pathology in living patients before physical symptoms surface.The diagnostic breakthrough, detailed in a study published in The Lancet Neurology, centers on an assay known as αSyn-SAA (alpha-synuclein seed amplification assay). By analysing cerebrospinal fluid, the test identifies abnormal protein aggregates, offering the first objective biological marker to confirm the disorder since British physician James Parkinson first described it in 1817.Building on these findings, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced in May that the PPMI study is officially being renamed the Parkinson’s Precision Medicine Initiative. The rebrand reflects a pivot from simply monitoring symptom progression to diagnosing, categorising and treating the disease through targeted biological interventions.
Brin Foundation and MJFF investment
The long-term development of the diagnostic test stems from massive private and philanthropic backing. Over the past 15 years, MJFF has funneled more than $800 million into assembling one of the most exhaustive Parkinson’s datasets in the world. This capital, including from the Sergey Brin’s foundation, helped drive PPMI cohort enrollment, finance remote testing networks and accelerate biological assay creation, creating an operational foundation that enabled the αSyn-SAA discovery.
Researchers spot abnormal protein seeds
Historically, medical teams relied on outward motor evaluations and patient-reported complaints to diagnose Parkinson’s, supplemented by DaTScan imaging to assess dopamine transporter loss. The αSyn-SAA tool changes that paradigm by pinpointing synuclein pathology, the second core biological indicator of the illness.In a broad trial cohort involving more than 1,100 PPMI participants, the test separated diagnosed patients from healthy controls with 88% sensitivity and 96% specificity. The researchers found that in subjects displaying classical Parkinson’s pathology, diagnostic sensitivity climbed past 90%.Crucially, the test regularly yielded positive results in individuals carrying genetic or clinical risk factors before tremors, stiffness, or cardinal movement symptoms ever showed up. The assay separates distinct molecular subtypes, helping researchers recognise why Parkinson’s progresses differently from person to person.Actor and foundation founder Michael J. Fox said he was “deeply moved by the breakthrough,” noting that biological precision helps make “a cure for Parkinson’s inevitable.” By establishing a reliable cellular endpoint, αSyn-SAA is poised to reshape pharmaceutical investment and therapy pipelines.The study was co-led by Dr. Andrew Siderowf, Director of the Parkinson Disease and Movement Disorders Center at the University of Pennsylvania, and Dr. Luis Concha, Director of Research and Development at Amprion.
